ARA-290

ARA-290

ARA-290

ʻO ARA-290 kahi peptide synthetic i haku ʻia 11 nā ʻakika amino, i loaʻa mai kahi kumu hoʻohālike ʻekolu-dimensional o ka erythropoietin hormone endogenous (EPO).

Pane wikiwiki

ʻO ARA-290 kahi peptide i loaʻa ʻole erythropoietic erythropoietic e huli ana i nā mea hoʻoponopono hou. Hoʻohana ia i ka neuroprotection ikaika, hoʻoikaika i ka hana hou ʻana o ke aʻalolo, hoʻomaha i ka ʻeha neuropathic a hoʻopaʻa i ka mumū, kūpono no ka ʻeha neural a me ka hoʻoponopono ʻana i ka ʻiʻo biomedical noiʻi.

SKU: 198804 Māhele:
Kaʻana like i kāu aloha

ʻO ARA-290 kahi peptide synthetic i haku ʻia 11 nā ʻakika amino, loaʻa mai kahi ʻano hoʻohālike ʻekolu-dimensional o ka hormone endogenous erythropoietin (EPO). Hoʻohālike ia i ka pilina paʻa o ka erythropoietin receptor β-co-receptor (βcR), koho koho i ka hoʻoponopono ʻana i ka protein receptor. ʻOi aku ka mea nui, ʻO kēia ʻano hana e hoʻopuni ana i nā pōʻino proliferative e pili pū ana me nā mea loaʻa EPO kuʻuna.

Ua hōʻike mua ʻia ma 2008, ʻO ka puka ʻana mai o ARA-290 e hōʻike ana i kahi hoʻololi hoʻolālā i ka noiʻi EPO mai ka hematopoietic therapy i ka hoʻoponopono ʻana i ka ʻiʻo immunomodulation.
Me ka mīkini, ma ka hoʻopaʻa ʻana me ka pili kiʻekiʻe i ka IRR, Ho'ā 'o ARA-290 i nā ala hōʻailona o lalo, komo JAK2-STAT3 a PI3K-Kanawai, e hoʻololi hope loa i nā mea hopena koʻikoʻi e like me NF-κB.

Ma waho aʻe o kēia, Hōʻike ka ARA-290 i nā hopena anti-inflammatory a me immunomodulatory, hoʻoikaika i ka hoʻoponopono neural a hoʻēmi i ka ʻeha neuropathic, hoʻoponopono i ka metabolism, a hōʻike i ka hiki therapeutic no ka mālama ʻana i ka liʻiliʻi fiber neuropathy, ʻO ka maʻi Charcot-Marie-Tooth, a me ka neuropathy diabetic.

Kaʻina

H-Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH

Helu CAS

1208243-50-8

ʻĀpana Molekala

C51H84N16O21

Kaumaha Molekala

1257.3

Noiʻi o ARA-290

1.Hoʻonui i ka Angiogenic Potential a Homing Capacity o Kaʻapuni ʻana i nā Pūnaehana Progenitor Endothelial:

  • ʻO ka mua, ʻO nā maʻi ischemic e hōʻike ana i nā maʻi vascular pōʻino. Me ka nui o ka momona a me ka maʻi diabetes, ke piʻi mau nei ka nui o nā maʻi i hoʻopilikia ʻia. No laila, no ka poʻe me ka maʻi vascular koʻikoʻi, ʻO ka ʻoki ʻana i kahi koho lapaʻau mua.
  • Ma kahi haʻawina pili, Hāʻawi ʻia ʻo ARA-290 i nā ʻiole me ischemia lālā mau (CLI). Ua hōʻike ʻia nā hopena e hoʻomaikaʻi nui ʻo ARA-290 i ka hoʻonui / neʻe ʻana a pale aku i ka apoptosis i hoʻokomo ʻia i ka hydrogen peroxide..
  • Eia hou, hoʻokahi injection o ARA-290 i hoʻomaikaʻi i ke kahe koko o nā lālā a me ka nui o ka capillary.
    Hui pū, Hōʻike kēia mau ʻike i ka hoʻohana ʻana i ka ARA-290 ma ke ʻano he adjuvant hiki ke hoʻonui i nā waiwai angiogenic intrinsic o Endothelial colony forming cell(ECFC) a me kā lākou hoʻi ʻana i vivo i nā pūnaewele ischemic, ma laila e hoʻoulu ai i ka angiogenesis. Pela, Hāʻawi kēia i kahi ala lapaʻau hou no nā maʻi ischemic mau loa.

2.Hoʻomaikaʻi i ka hoʻokuʻu ʻana o ka insulin a me ka hoʻomanawanui ʻana o ka glucose ma ke ʻano 2 Nā maʻi maʻi diabetes:
I ka pae metabolic, Hoʻonui nui ʻo ARA-290 i ka ʻae ʻana i ka glucose i nā ʻiole maʻi maʻi me ka ʻole e pili ana i nā ʻiole maʻi maʻi ʻole.. Kūkākūkā, hoʻoulu ʻia i ke kiʻekiʻe GSIS(ʻO ka hoʻoulu ʻana o ka insulin i ka glucose) pae, ka hopena e hoʻomaikaʻi i ka glucose oxidation a ʻO Adenosine triphosphate(ATP) hana ʻana. Ma o keia hana, ma ka hooikaika ana ATP-sensitive potassium channel(CAT) pani ʻana i ke kahawai, ʻo ia ka hopena i ka huna ʻana o ka insulin.

3.Nā hopena anti-inflammatory a me nā neuroprotective:
E loiloi i ka neuroinflammation, i loko o kahi hoʻokolohua lapaʻau e pili ana i nā ʻiole Lewis me hoʻokolohua autoimmune encephalomyelitis (EAE), ʻO ka hoʻomau mau ʻana o nā injections ARA-290 i hōʻemi nui i ka paʻakikī o ka EAE i nā ʻiole. I ke ʻano wae, ua hōʻemi kēia lapaʻau i ka hōʻiliʻili ʻana o nā cell inflammatory i ka spinal cord EAE a hoʻopaʻa i ka hoʻonui a me ka hōʻike ʻana o nā cytokines e like me interleukin., kumu necrosis kumu-α, a hiki ʻole nitric oxide synthase ma ke kuamoʻo ʻiole EAE.

Eia kekahi, Ua hōʻike ʻia nā haʻawina in vitro i ka ARA-290 inhibits Kelepona Th1 a me Th7 polarization ma EAE lymphocytes. Hui pu, Ke hōʻike nei kēia hoʻokolohua he waiwai lapaʻau ko ka ARA-290 no ka sclerosis lehulehu.

4.Hoʻoikaika i ka hoʻoponopono ʻana i ka neural a me ka hoʻēmi ʻana i ka ʻeha Neuropathic:
ʻIke ʻia, Hiki iā ARA-290 ke hele pololei i ka pale koko-lolo, hiki iā ia ke hana pololei ganglia aʻa hope a microglia. Ma laila, hoʻopaʻa ia i nā hoʻokuʻu ʻino ʻole i loko o ka lolo o ka lolo, hoemi ana ʻike kikowaena, a hoʻololi ikaika i nā mea neurotrophic i ka wā e hoʻemi ana i ka mumū i loko o ka ganglia aʻa dorsal e hoʻoponopono i ka ʻōnaehana nerve waena..

5.Hoʻonui i ka hoʻoponopono ʻana a me ka hiki ke hana hou:
ʻO ka hope loa, Hana ʻo ARA-290 i nā cell immune innate e hōʻike ana i ka IRR, ka mea e paipai ikaika ana i ko lakou polarization mai ka pro-inflammatory M1 phenotype i ka anti-inflammatory a me ka pro-repair M2 phenotype. Ma ka hopena, hoʻopau ia i nā pane inflammatory excessive i ka hoʻoulu ʻana i ka huna ʻana o nā kumu ulu nui, ka hoʻomaʻemaʻe ʻana i nā cell apoptotic, a me ka hana ʻana i nā aʻa koko hou. ʻO ka hope loa, hoʻomaikaʻi kēia i ka paʻa o ke kūkulu ʻana a me nā waiwai mechanical o nā ʻiʻo i hoʻoponopono ʻia.

COA

HPLC

MS

(1) Ax, ʻO G.; Garrigue, P.; Bennis, Y.; Stalin, J.; ʻO ka puʻuwai, A.; Kerami, A.; Brines, M.; Blot-Chabaud, M.; Sabatier, F.; Dignat-George, F.; et al. ARA290, he Agonist kiko'ī o Erythropoietin/CD131 Heteroreceptor, Hoʻomaikaʻi i ka Circulating Endothelial Progenitors 'Angiogenic Potential a me ka Homing hiki. Haʻalulu 2016, 46 (4), 390-397. DOI: 10.1097/CS.0000000000000606.

(2) Muller, C.; ʻO Yassin, K.; Li, L.-S.; Lau pama, M.; Efendic, S.; Lala mauna, MAHOPE.; Kerami, A.; Brines, M.; ʻOstenson, C.-G. Hoʻomaikaʻi ʻo ARA290 i ka hoʻokuʻu ʻana o ka insulin a me ka hoʻomanawanui ʻana o ka glucose i ke ʻano 2 ʻIole ʻo Goto-Kakizaki Diabetic. Lapaau Molekala 2015, 21 (1), 969-978. DOI: 10.2119/molmed.2015.00267.

(3) ʻO Chen, H.; ʻO Luo, B.; ʻO ka mea, X.; Xiong, J.; Liu, Z.; ʻO Jiang, M.; Shi, R.; ʻO Yan, C.; ʻO Wu, Y.; ʻO Zhang, Z. Nā hopena lapaʻau o nonerythropoietic erythropoietin analog ARA290 i ka ʻiole autoimmune encephalomyelitis hoʻokolohua.. Nūpepa o Neuroimmunology 2014, 268 (1-2), 64-70. DOI: 10.1016/j.jneuroim.2014.01.006.

(4) deVries, M. R.; de Jong, R. C. M.; Peters, H. A. B.; Hamming, J. F.; ʻO Goumans, M. J.; Quax, P. H. A. ʻO ka hoʻopaʻa ʻana o Vegfr2 i ka ʻāʻī ʻana o ka vein murine ka hopena i ka emi ʻana o ka hemorrhage intraplaque a me nā ʻeha atherosclerotic paʻa.. Atherosclerosis 2014, 235 (2), e161-e162. DOI: 10.1016/j.atherosclerosis.2014.05.463.

(5) Bastiaansen, Ua ʻōlelo ʻo T.; Carp, J.; Weasel, A.; de Boer, H.; honua, S.; Aref, Z.; de Jong, R.; Peters, E.; deVries, M.; van Oeveren-Rietdijk, A.; et al. TLR4 Molekula Kokoi RP105 (CD180) Hoʻoponopono i ka Arteriogenesis a me Angiogenesis. ʻEpelika Journal of Vascular and Endovascular Surgery 2014, 47 (6), 695-696. DOI: 10.1016/j.ejvs.2014.03.033.

(6) Lawe au, M.; Thiemermann, C.; Kerami, A.; Brines, M. Ke hoʻololi nei i ka hoʻololi molekala no ka pale ʻana a me ka hoʻoponopono ʻana i nā ʻiʻo: Nā hopena lōʻihi o kahi peptide liʻiliʻi non-erythropoietic i ʻenekinia ʻia mai ka erythropoietin. Pharmacology & Nā lāʻau lapaʻau 2015, 151, 32-40. DOI: 10.1016/j.pharmthera.2015.02.005.

kikoʻī

12mg

Home Huli Whatsapp Nā lawelawe Huahana